This phase 2, multicenter, open-label, randomized study at Long Beach Memorial Medical Center and Orange Coast Memorial Medical Center will assess the effect of bortezomib, dexamethasone, and elotuzumab, (BdE; investigational arm) compared with bortezomib and dexamethasone (Bd; control group) in subjects with relapsed/refractory multiple myeloma (MM). The study will compare progression-free survival (PFS) between treatment arms in the overall population while also estimating other statistical relevant information in a subgroup with a portion of DNA that is associated with approved clinical response. Each patient will take part in a screening period, when the study doctor will determine eligibility status. If patients are eligible, they will return to the study clinic on Day 1 for additional study assessments before beginning study drug that day.
A phase 2, randomized study of Bortezomib/Dexamethasone with or without Elotuzumab in subjects with relapsed/refractory Multiple Myeloma (CA204009)
Long Beach Memorial, Orange Coast MemorialCurrently enrolling additional patients: